Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has experienced a 60% sales increase in India between April and May.

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

A Mounjaro user has revealed what happened when they accidentally overdosed using the controversial 'golden dose'. ICYMI, ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...